In-111 DTPA-Octreotide Scintigraphy for Disease Detection in Metastatic Thyroid Cancer: Comparison with F-18 FDG Positron Emission Tomography and Extensive Conventional Radiographic Imaging

Clinical Nuclear Medicine

Volumn 28, Issue 3, 2003, Pages 208-217

  Sarlis, Nicholas J ^a,c   Gourgiotis, Loukas ^a   Guthrie, Lori C ^a   Galen, Barbara ^b   Skarulis, Monica C ^a   Shawker, Thomas H ^b   Patronas, Nicholas J ^b   Reynolds, James C ^b  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Computed Tomography; Magnetic Resonance Imaging; Octreoscan; Positron Emission Tomography; Thyroid Cancer

Indexed keywords

DIATRIZOATE; FLUORODEOXYGLUCOSE F 18; GADOLINIUM PENTETATE; PENTETREOTIDE IN 111; DIAGNOSTIC AGENT; DRUG DERIVATIVE; OCTREOTIDE; PENTETIC ACID; RADIOPHARMACEUTICAL AGENT; SDZ 215 811; SDZ 215-811;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DRUG UPTAKE; FEMALE; HUMAN; MALE; METASTASIS; POSITRON EMISSION TOMOGRAPHY; RADIODIAGNOSIS; RADIOGRAPHY; SCINTIGRAPHY; SENSITIVITY AND SPECIFICITY; THYROID CANCER; BONE TUMOR; CARCINOMA; CLINICAL TRIAL; COHORT ANALYSIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; HEAD AND NECK TUMOR; LUNG TUMOR; LYMPH NODE METASTASIS; MEDIASTINUM TUMOR; METHODOLOGY; MIDDLE AGED; PLEURA TUMOR; SCINTISCANNING; SKIN TUMOR; THYROID TUMOR;

BONE NEOPLASMS; CARCINOMA; COHORT STUDIES; FEMALE; FLUORODEOXYGLUCOSE F18; HEAD AND NECK NEOPLASMS; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MEDIASTINAL NEOPLASMS; MIDDLE AGED; OCTREOTIDE; PENTETIC ACID; PLEURAL NEOPLASMS; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; SKIN NEOPLASMS; THYROID NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0038605690     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003072-200303000-00008     Document Type: Article

References (58)

1. Ries LAG, Eisner MP, Kosary CL, et al: SEER Cancer Statistics Review 1973-1998 [entire volume]. Betheda, MD: National Cancer Institute, 2001.
2. Sarlis NJ: Metastatic thyroid cancer unresponsive to conventional therapies: novel management approaches through translational clinical research. Curr Drug Targets Immun Endocr Metab Dis 1:103, 2001.
3. Baudin E, Schlumberger M, Lumbroso J, et al: Octreotide scintigraphy in patients with differentiated thyroid carcinoma: contribution for patients with negative radioiodine scan. J Clin Endocrinol Metab 81:2541, 1996.
4. Reubi JC, Schaer JC, Waser B, et al: Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization. Cancer Res 54:3455, 1994.
5. Wang W, Macapinlac H, Larson SM, et al: [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab 84:2291, 1999.
6. Sherman SI, Brierley JD, Sperling M, et al: Prospective multicenter study of thyroid carcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. Cancer 83:1012, 1998.
7. Dadparvar S, Chevres A, Tulchinsky M, et al: Clinical utility of technetium-99m methoxisobutylisonitrile imaging in differentiated thyroid carcinoma: comparison with thallium-201 and iodine-131 Na scintigraphy, and serum thyroglobulin quantitation. Eur J Nucl Med 22:1330, 1995.
8. Spencer CA, Takeuchi M, Kazarosyan M: Current status and performance goals for serum thyroglobulin assays. Clin Chem 42:164, 1996.
9. Riddell C, Carson RE, Carrasquillo JA, et al: Noise reduction in oncology FDG PET images by iterative reconstruction: a quantitative assessment. J Nucl Med 42:1316, 2001.
10. DeGrado TR, Turkington TG, Williams JJ, et al: Performance characteristics of a whole-body PET scanner. J Nucl Med 35:1398, 1994.
11. de Jong M, Breeman WA, Bakker WH, et al: Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. Cancer Res 58:437, 1998.
12. Mazzaferri EL, Jhiang SM: Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 97:418, 1994.
13. Haugen BR, Lin EC: Isotope imaging for metastatic thyroid cancer. Endocrinol Metab Clin North Am 30:469, 2001.
14. Weber AL, Randolph G, Aksoy FG: The thyroid and parathyroid glands. CT and MR imaging and correlation with pathology and clinical findings. Radiol Clin North Am 38:1105, 2000.
15. DeGroot LJ, Reilly M: Use of isotope bone scans and skeletal survey X-rays in the follow-up of patients with thyroid carcinoma. J Endocrinol Invest 7:175, 1984.
16. Reynolds JC, Robbins J: The changing role of radioiodine in the management of differentiated thyroid cancer. Semin Nucl Med 27:152, 1997.
17. Mallin WH, Elgazzar AH, Maxon HR III: Imaging modalities in the follow-up of non-iodine avid thyroid carcinoma. Am J Otolaryngol 15:417, 1994.
18. Castillo LA, Yeh SD, Leeper RD, et al: Bone scans in bone metastases from functioning thyroid carcinoma. Clin Nucl Med 5:200, 1980.
19. Moog F, Linke R, Manthey N, et al: Influence of thyroid-stimulating hormone levels on uptake of FDG in recurrent and metastatic differentiated thyroid carcinoma. J Nucl Med 41:1989, 2000.
20. Mellanen P, Minn H, Grenman R, et al: Expression of glucose transporters in head-and-neck tumors. Int J Cancer 56:622, 1994.
21. Haber RS, Weiser KR, Pritsker A, et al: GLUT1 glucose transporter expression in benign and malignant thyroid nodules. Thyroid 7:363, 1997.
22. Feine U, Lietzenmayer R, Hanke JP, et al: Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med 37:1468, 1996.
23. Joensuu H, Ahonen A: Imaging of metastases of thyroid carcinoma with fluorine-18 fluorodeoxyglucose. J Nucl Med 28:910, 1987.
24. Weber WA, Schwaiger M, Avril N: Quantitative assessment of tumor metabolism using FDG-PET imaging. Nucl Med Biol 27:683, 2000.
25. Jadvar H, McDougall IR, Segall GM: Evaluation of suspected recurrent papillary thyroid carcinoma with [18F]fluorodeoxyglucose positron emission tomography. Nucl Med Commun 19:547, 1998.
26. Schluter B, Bohuslavizki KH, Beyer W, et al: Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan. J Nucl Med 42:71, 2001.
27. Lind P, Gallowitsch HJ, Mikosch P, et al: Comparison of different tracers in the follow up of differentiated thyroid carcinoma. Acta Med Austriaca 26:115, 1999.
28. McDougall IR, Davidson J, Segall GM: Positron emission tomography of the thyroid, with an emphasis on thyroid cancer. Nucl Med Commun 22:485, 2001.
29. Conti PS, Durski JM, Bacqai F, et al: Imaging of locally recurrent and metastatic thyroid cancer with positron emission tomography. Thyroid 9:797, 1999.
30. Chung JK, So Y, Lee JS, et al: Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan. J Nucl Med 40:986, 1999.
31. Grunwald F, Schomburg A, Bender H, et al: Fluorine-18 fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 23:312, 1996.
32. Altenvoerde G, Lerch H, Kuwert T, et al: Positron emission tomography with F-18-deoxyglucose in patients with differentiated thyroid carcinoma, elevated thyroglobulin levels, and negative iodine scans. Langenbecks Arch Surg 383:160, 1998.
33. Wang W, Larson SM, Fazzari M, et al: Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab 85:1107, 2000.
34. Pineda JD, Lee T, Ain K, et al: Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab 80:1488, 1995.
35. Helal BO, Merlet P, Toubert ME, et al: Clinical impact of (18)F-FDG-PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative (131)I scanning results after therapy. J Nucl Med 42:1464, 2001.
36. Muros MA, Llamas-Elvira JM, Ramirez-Navarro A, et al: Utility of fluorine-18-fluorodeoxyglucose positron emission tomography in differentiated thyroid carcinoma with negative radioiodine scans and elevated serum thyroglobulin levels. Am J Surg 179:457, 2000.
37. Yeo JS, Chung JK, So Y, et al: F-18-fluorodeoxyglucose positron emission tomography as a presurgical evaluation modality for I-131 scan-negative thyroid carcinoma patients with local recurrence in cervical lymph nodes. Head Neck 23:94, 2001.
38. Breeman WA, de Jong M, Kwekkeboom DJ, et al: Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. Eur J Nucl Med 28:1421, 2001.
39. Gorges R, Kahaly G, Muller-Brand J, et al: Somatostatin receptor status in non-medullary thyroid carcinoma [in German]. Nuklearmedizin 38:15, 1999.
40. Ain KB, Taylor KD: Somatostatin analogs affect proliferation of human thyroid carcinoma cell lines in vitro. J Clin Endocrinol Metab 78:1697, 1994.
41. Ain KB, Taylor KD, Tofiq S, et al: Somatostatin receptor subtype expression in human thyroid and thyroid carcinoma cell lines. J Clin Endocrinol Metab 82:1857, 1997.
42. Siperstein AE, Levin KE, Gum ET, et al: Effect of somatostatin on adenylate cyclase activity in normal and neoplastic thyroid tissue. World J Surg 16:555, 1992.
43. degli Uberti EC, Hanau S, Rossi R, et al: Somatostatin reduces 3H-thymidine incorporation and c-myc, but not thyroglobulin ribonucleic acid levels in human thyroid follicular cells in vitro. J Clin Endocrinol Metab 72:1364, 1991.
44. Tsuzaki S, Moses AC: Somatostatin inhibits deoxyribonucleic acid synthesis induced by both thyrotropin and insulin-like growth factor-I in FRTL5 cells. Endocrinology 126:3131, 1990.
45. Reubi JC, Schaer JC, Laissue JA, et al: Somatostatin receptors and their subtypes in human tumors and in peritumoral vessels. Metabolism 45(8 Suppl 1):39, 1996.
46. Knoll MR, Schwab M, Oestreich K, et al: HLA class II expression in well differentiated thyroid carcinoma: correlation with clinicopathological features. J Exp Clin Cancer Res 16:177, 1997.
47. Gorges R, Kahaly G, Muller-Brand J, et al: Radionuclide-labeled somatostatin analogues for diagnostic and therapeutic purposes in nonmedullary thyroid cancer. Thyroid 11:647, 2001.
48. Postema PT, De Herder WW, Reubi JC, et al: Somatostatin receptor scintigraphy in non-medullary thyroid cancer. Digestion 57(Suppl 1):36, 1996.
49. Haslinghuis LM, Krenning EP, De Herder WW, et al: Somatostatin receptor scintigraphy in the follow-up of patients with differentiated thyroid cancer. J Endocrinol Invest 24:415, 2001.
50. Garin E, Devillers A, Le Cloirec J, et al: Use of indium-111 pentetreotide somatostatin receptor scintigraphy to detect recurrent thyroid carcinoma in patients without detectable iodine uptake. Eur J Nucl Med 25:687, 1998.
51. Tenenbaum F, Lumbroso J, Schlumberger M, et al: Radiolabeled somatostatin analog scintigraphy in differentiated thyroid carcinoma. J Nucl Med 36:807, 1995.
52. Kwekkeboom DJ, Kooij PP, Bakker WH, et al: Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake. J Nucl Med 40:762, 1999.
53. De Jong M, Bernard BF, De Bruin E, et al: Internalization of radiolabelled [DTPA0]octreotide and [DOTA0,Tyr3]octreotide: peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy. Nucl Med Commun 19:283, 1998.
54. Hofmann M, Maecke H, Borner R, et al: Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur J Nucl Med 28:1757, 2001.
55. Robbins RJ, Hill RH, Wang W, et al: Inhibition of metabolic activity in papillary thyroid carcinoma by a somatostatin analogue. Thyroid 10:177, 2000.
56. Valli N, Catargi B, Ronci N, et al: Evaluation of indium-111 pentetreotide somatostatin receptor scintigraphy to detect recurrent thyroid carcinoma in patients with negative radioiodine scintigraphy. Thyroid 9:583, 1999.
57. Thompson BH, Stanford W: MR imaging of pulmonary and mediastinal malignancies. Magn Reson Imaging Clin North Am 8:729, 2000.
58. Gambhir SS, Czernin J, Schwimmer J, et al: A tabulated summary of the FDG PET literature. J Nucl Med 42(5 Suppl):1S, 2001.